January 7, 2019 01:45 PM ESTUpdated January 9, 11:59 AM
News Briefing

Pos­i­tive oc­u­lar im­plant da­ta bring Al­ler­gan one step clos­er to NDA; Vivek Ra­maswamy spawns an­oth­er 'Van­t'

Natalie Grover

Reporter

→ In 2016, Brent Saun­der’s Al­ler­gan $AGN or­ches­trat­ed a string of deals af­ter its $160 bil­lion merg­er with Pfiz­er fell through thanks to Oba­ma-era tax …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times